FDA ap­proves Takeda's new en­zyme re­place­ment ther­a­py for rare blood clot­ting dis­or­der

The FDA on Thurs­day ap­proved Take­da’s Adzyn­ma, an en­zyme re­place­ment ther­a­py for adult and pe­di­atric pa­tients with con­gen­i­tal throm­bot­ic throm­bo­cy­topenic pur­pu­ra (cTTP), which is a rare and po­ten­tial­ly fa­tal blood clot­ting dis­or­der.

The ap­proval was based on da­ta an­nounced by Take­da in Jan­u­ary from an in­ter­im Phase III analy­sis that found the ther­a­py re­duced in­stances of low blood platelet count for pa­tients with cTTP com­pared to stan­dard-of-care plas­ma-based ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER